Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - US
$ 59.1
0.323 %
$ 10.7 B
Market Cap
-25.92
P/E
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services.[ Read More ]
The intrinsic value of one CTLT stock under the base case scenario is HIDDEN Compared to the current market price of 59.1 USD, Catalent, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CTLT
FINANCIALS
4.38 B
REVENUE
145 M
OPERATING INCOME
-1.04 B
NET INCOME
268 M
OPERATING CASH FLOW
-327 M
INVESTING CASH FLOW
74 M
FINANCING CASH FLOW
1.02 B
REVENUE
-71 M
OPERATING INCOME
-129 M
NET INCOME
61 M
OPERATING CASH FLOW
-34 M
INVESTING CASH FLOW
-10 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Catalent, Inc.
| Current Assets | 2.6 B |
| Cash & Short-Term Investments | 289 M |
| Receivables | 1.57 B |
| Other Current Assets | 742 M |
| Non-Current Assets | 7.16 B |
| Long-Term Investments | 156 M |
| PP&E | 3.72 B |
| Other Non-Current Assets | 3.28 B |
| Current Liabilities | 1.03 B |
| Accounts Payable | 361 M |
| Short-Term Debt | 61 M |
| Other Current Liabilities | 609 M |
| Non-Current Liabilities | 5.12 B |
| Long-Term Debt | 4.93 B |
| Other Non-Current Liabilities | 191 M |
EFFICIENCY
Earnings Waterfall
Catalent, Inc.
| Revenue | 4.38 B |
| Cost Of Revenue | 3.43 B |
| Gross Profit | 953 M |
| Operating Expenses | 808 M |
| Operating Income | 145 M |
| Other Expenses | 1.19 B |
| Net Income | -1.04 B |
RATIOS
21.75%
GROSS MARGIN
3.31%
OPERATING MARGIN
-23.81%
NET MARGIN
-28.94%
ROE
-10.69%
ROA
1.80%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Catalent, Inc.
| Net Income | -1.04 B |
| Depreciation & Amortization | 489 M |
| Capital Expenditures | -327 M |
| Stock-Based Compensation | 68 M |
| Change in Working Capital | -62 M |
| Others | 678 M |
| Free Cash Flow | -59 M |
Wall Street Analysts Price Targets
Catalent, Inc.
Wall Street analysts predict an average 1-year price target for CTLT of $63.5 , with forecasts ranging from a low of $63.5 to a high of $63.5 .
CTLT Lowest Price Target
Wall Street Target
63.5 USD
7.45%
CTLT Average Price Target
Wall Street Target
63.5 USD
7.45%
CTLT Highest Price Target
Wall Street Target
63.5 USD
7.45%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Catalent, Inc.
Sold
0-3 MONTHS
139 K USD 2
3-6 MONTHS
1.24 M USD 7
6-9 MONTHS
21.7 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
4 weeks ago
Oct 18, 2024
|
Sell 19.2 K USD
|
Ferraro Joseph Anthony
SVP, General Counsel, CCO |
- 320
|
59.97 USD |
|
1 month ago
Sep 26, 2024
|
Sell 120 K USD
|
McErlane David
Group President, Biologics |
- 1994
|
59.97 USD |
|
3 months ago
Aug 02, 2024
|
Sell 39.4 K USD
|
Hopson Ricky
Pres. BioProduct Delivery, CoS |
- 662
|
59.56 USD |
|
3 months ago
Aug 02, 2024
|
Sell 39.7 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 666
|
59.55 USD |
|
3 months ago
Aug 02, 2024
|
Sell 36.2 K USD
|
Ferraro Joseph Anthony
SVP, General Counsel, CCO |
- 608
|
59.58 USD |
|
3 months ago
Aug 02, 2024
|
Sell 230 K USD
|
Evoli Lisa
SVP, Chief HR Officer |
- 3859
|
59.67 USD |
|
3 months ago
Aug 02, 2024
|
Sell 69.6 K USD
|
Gennadios Aristippos
Group Pres. Pharma & Consumer |
- 1169
|
59.55 USD |
|
3 months ago
Jul 29, 2024
|
Sell 534 K USD
|
Maselli Alessandro
President & CEO |
- 9088
|
58.76 USD |
|
3 months ago
Jul 29, 2024
|
Sell 12.1 K USD
|
Hopson Ricky
Pres. BioProduct Delivery, CoS |
- 206
|
58.67 USD |
|
3 months ago
Jul 29, 2024
|
Sell 16.6 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 283
|
58.69 USD |
|
3 months ago
Jul 29, 2024
|
Sell 20.5 K USD
|
Gennadios Aristippos
Group Pres. Pharma & Consumer |
- 349
|
58.7 USD |
|
4 months ago
Jul 08, 2024
|
Sell 170 K USD
|
Masanovich Matti
SVP, Chief Financial Officer |
- 2993
|
56.74 USD |
|
5 months ago
Jun 04, 2024
|
Sell 76 K USD
|
Hopson Ricky
Pres. BioProduct Delivery, CoS |
- 1401
|
54.2631 USD |
|
8 months ago
Mar 15, 2024
|
Sell 21.7 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 387
|
56.2 USD |
|
1 year ago
Aug 31, 2023
|
Bought 50 K USD
|
Ryan Michelle R
Director |
+ 1000
|
49.98 USD |
|
1 year ago
Aug 30, 2023
|
Bought 1.06 M USD
|
GREISCH JOHN J
Executive Chair |
+ 21000
|
50.24 USD |
|
1 year ago
Aug 24, 2023
|
Sell 87.7 K USD
|
Maselli Alessandro
President & CEO |
- 1970
|
44.51 USD |
|
1 year ago
Aug 24, 2023
|
Sell 4.56 K USD
|
Maselli Alessandro
President & CEO |
- 101
|
45.15 USD |
|
1 year ago
Aug 24, 2023
|
Sell 12 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 269
|
44.57 USD |
|
1 year ago
Aug 24, 2023
|
Sell 17.4 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 390
|
44.5 USD |
|
1 year ago
Aug 24, 2023
|
Sell 17.6 K USD
|
Gennadios Aristippos
Group Pres. Pharma & Consumer |
- 396
|
44.49 USD |
|
1 year ago
Aug 24, 2023
|
Sell 36.5 K USD
|
Fasman Steven L
EVP & Chief Admin Officer |
- 817
|
44.65 USD |
|
1 year ago
Aug 24, 2023
|
Sell 9.66 K USD
|
Carletti Lorenzo
SVP Global Ops Ph & Cons Hlth |
- 216
|
44.71 USD |
|
1 year ago
Aug 24, 2023
|
Sell 3.9 K USD
|
Arnold Jonathan
SVP, CCO & Div. Head BioP Del. |
- 87
|
44.87 USD |
|
1 year ago
Aug 24, 2023
|
Sell 12.3 K USD
|
Hopson Ricky
Pres. Clinical Dev Supply Div |
- 276
|
44.56 USD |
|
1 year ago
Aug 24, 2023
|
Sell 6.57 K USD
|
Hawkeswood Thomas W
Pres. Pharma Prod Delivery Div |
- 147
|
44.72 USD |
|
1 year ago
Aug 24, 2023
|
Sell 8.5 K USD
|
Lickfold Charles
SVP, CIO |
- 190
|
44.72 USD |
|
1 year ago
Aug 24, 2023
|
Sell 4.75 K USD
|
Hunt Patricia
Pres. Consumer Health Div |
- 106
|
44.77 USD |
|
1 year ago
Aug 24, 2023
|
Sell 16.9 K USD
|
Pravda Ricardo
Chief Transformation Officer |
- 379
|
44.47 USD |
|
1 year ago
Aug 01, 2023
|
Sell 2.19 K USD
|
Pravda Ricardo
Chief Transformation Officer |
- 47
|
46.5 USD |
|
1 year ago
Aug 01, 2023
|
Sell 10.6 K USD
|
Pravda Ricardo
Chief Transformation Officer |
- 222
|
47.78 USD |
|
1 year ago
Aug 01, 2023
|
Sell 41.1 K USD
|
Maselli Alessandro
President & CEO |
- 879
|
46.71 USD |
|
1 year ago
Aug 01, 2023
|
Sell 28.9 K USD
|
Maselli Alessandro
President & CEO |
- 606
|
47.75 USD |
|
1 year ago
Aug 01, 2023
|
Sell 6.47 K USD
|
Lickfold Charles
SVP, CIO |
- 135
|
47.9 USD |
|
1 year ago
Aug 01, 2023
|
Sell 7.72 K USD
|
Hunt Patricia
Pres. Consumer Health Div |
- 161
|
47.95 USD |
|
1 year ago
Aug 01, 2023
|
Sell 9.33 K USD
|
Hopson Ricky
Pres. Clinical Dev Supply Div |
- 195
|
47.86 USD |
|
1 year ago
Aug 01, 2023
|
Sell 12.4 K USD
|
Hawkeswood Thomas W
Pres. Pharma Prod Delivery Div |
- 258
|
47.97 USD |
|
1 year ago
Aug 01, 2023
|
Sell 9.1 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 190
|
47.9 USD |
|
1 year ago
Aug 01, 2023
|
Sell 1.63 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 35
|
46.64 USD |
|
1 year ago
Aug 01, 2023
|
Sell 11.5 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 241
|
47.88 USD |
|
1 year ago
Aug 01, 2023
|
Sell 2.84 K USD
|
Gennadios Aristippos
Group Pres. Pharma & Consumer |
- 61
|
46.58 USD |
|
1 year ago
Aug 01, 2023
|
Sell 10.5 K USD
|
Gennadios Aristippos
Group Pres. Pharma & Consumer |
- 220
|
47.87 USD |
|
1 year ago
Aug 01, 2023
|
Sell 18.3 K USD
|
Carletti Lorenzo
SVP Global Ops Ph & Cons Hlth |
- 383
|
47.77 USD |
|
1 year ago
Aug 01, 2023
|
Sell 2.96 K USD
|
Arnold Jonathan
SVP, CCO & Div. Head BioP Del. |
- 62
|
47.8 USD |
|
1 year ago
Aug 01, 2023
|
Sell 52 K USD
|
Fasman Steven L
EVP & Chief Admin Officer |
- 1113
|
46.72 USD |
|
1 year ago
Aug 01, 2023
|
Sell 25 K USD
|
Fasman Steven L
EVP & Chief Admin Officer |
- 524
|
47.76 USD |
|
1 year ago
May 01, 2023
|
Sell 72.1 K USD
|
Boerman Manja
Pres. BioModalities Division |
- 1446
|
49.86 USD |
|
1 year ago
May 01, 2023
|
Sell 33.8 K USD
|
Gargiulo Mario
SVP, Ops, Biologics Europe |
- 678
|
49.86 USD |
|
1 year ago
Jan 23, 2023
|
Sell 31.7 K USD
|
Hopson Ricky
Pres. Clinical Dev Supply Div |
- 643
|
49.36 USD |
|
1 year ago
Dec 05, 2022
|
Sell 40.3 K USD
|
Boerman Manja
Pres. BioModalities Division |
- 780
|
51.7 USD |
|
2 years ago
Oct 31, 2022
|
Sell 161 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 2451
|
65.83 USD |
|
2 years ago
Oct 10, 2022
|
Sell 72 K USD
|
Hawkeswood Thomas W
Pres. Pharma Prod Delivery Div |
- 930
|
77.46 USD |
|
2 years ago
Aug 31, 2022
|
Sell 199 K USD
|
Hopson Ricky
Pres. Clinical Dev Supply Div |
- 2216
|
89.59 USD |
|
2 years ago
Aug 26, 2022
|
Sell 259 K USD
|
Riley Michael A.
Pres. Bio Product Delivery Div |
- 2491
|
104.07 USD |
|
2 years ago
Aug 26, 2022
|
Sell 171 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 1639
|
104.07 USD |
|
2 years ago
Aug 24, 2022
|
Sell 136 K USD
|
Schmidt Kay A
SVP, Enterprise Functions |
- 1321
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 153 K USD
|
Riley Michael A.
Pres. Bio Product Delivery Div |
- 1482
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 180 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 1747
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 479 K USD
|
Maselli Alessandro
President & CEO |
- 4646
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 34.9 K USD
|
Hunt Patricia
Pres. Consumer Health Div |
- 339
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 156 K USD
|
Hopson Ricky
Pres. Clinical Dev Supply Div |
- 1517
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 69.1 K USD
|
Hawkeswood Thomas W
Pres. Pharma Prod Delivery Div |
- 671
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 190 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 1840
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 172 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 1670
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 170 K USD
|
Gennadios Aristippos
Group Pres. Pharma & Consumer |
- 1645
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 163 K USD
|
Gargiulo Mario
SVP Global Ops Biologics |
- 1586
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 496 K USD
|
Fasman Steven L
EVP & Chief Admin Officer |
- 4811
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 4.01 M USD
|
Chiminski John R
Executive Chair |
- 38934
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 146 K USD
|
Castellano Thomas P
SVP, Chief Financial Officer |
- 1414
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 106 K USD
|
Carletti Lorenzo
SVP Global Ops Ph & Cons Hlth |
- 1033
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 340 K USD
|
Boerman Manja
Pres. BioModalities Division |
- 3296
|
103.04 USD |
|
2 years ago
Aug 24, 2022
|
Sell 39.6 K USD
|
Arnold Jonathan
SVP & Chief Commercial Ofcr |
- 384
|
103.04 USD |
|
2 years ago
Jul 26, 2022
|
Sell 34.5 K USD
|
Schmidt Kay A
SVP, Enterprise Functions |
- 323
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 45.6 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 427
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 87.2 K USD
|
Maselli Alessandro
President & CEO |
- 816
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 33.4 K USD
|
Hopson Ricky
Pres, Clinical Dev & Supply |
- 312
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 42.4 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 394
|
107.67 USD |
|
2 years ago
Jul 26, 2022
|
Sell 41.8 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 388
|
107.67 USD |
|
2 years ago
Jul 26, 2022
|
Sell 43.7 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 409
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 43.1 K USD
|
Gennadios Aristippos
Group Pres. Pharma & Consumer |
- 403
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 104 K USD
|
Gargiulo Mario
SVP Global Ops Biologics |
- 969
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 272 K USD
|
Fasman Steven L
EVP & Chief Admin Officer |
- 2546
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 1.04 M USD
|
Chiminski John R
Executive Chair |
- 9691
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 37.1 K USD
|
Castellano Thomas P
SVP, Chief Financial Officer |
- 347
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 67.5 K USD
|
Carletti Lorenzo
SVP Global Ops Ph & Cons Hlth |
- 631
|
106.9 USD |
|
2 years ago
Jul 26, 2022
|
Sell 10 K USD
|
Arnold Jonathan
SVP & Chief Commercial Ofcr |
- 94
|
106.9 USD |
|
2 years ago
Jun 10, 2022
|
Sell 12.6 K USD
|
Gargiulo Mario
SVP Global Ops Large Molecule |
- 118
|
106.59 USD |
|
2 years ago
Jun 10, 2022
|
Sell 326 K USD
|
Fasman Steven L
SVP & General Counsel |
- 3049
|
106.77 USD |
|
2 years ago
Feb 06, 2022
|
Sell 50 M USD
|
Zippelius Peter
Director |
- 487092
|
102.65 USD |
|
2 years ago
Jan 31, 2022
|
Sell 240 K USD
|
Hopson Ricky
VP, Chief Accounting Officer |
- 2325
|
103.39 USD |
|
2 years ago
Jan 21, 2022
|
Sell 18.8 K USD
|
Whitlow Ricci S
President, CSS |
- 184
|
102.37 USD |
|
2 years ago
Jan 10, 2022
|
Sell 288 K USD
|
Flynn Karen
Chief Commercial Officer |
- 2472
|
116.64 USD |
|
2 years ago
Nov 30, 2021
|
Sell 388 M USD
|
Zippelius Peter
Director |
- 3000000
|
129.3 USD |
|
2 years ago
Nov 23, 2021
|
Sell 339 K USD
|
LUCIER GREGORY T
Director |
- 2668
|
126.98 USD |
|
2 years ago
Nov 23, 2021
|
Sell 307 K USD
|
LUCIER GREGORY T
Director |
- 2400
|
127.76 USD |
|
3 years ago
Nov 01, 2021
|
Sell 1.49 M USD
|
Arnold Jonathan
Pres. Oral & Specialty Deliv. |
- 10672
|
140.02 USD |
|
3 years ago
Oct 20, 2021
|
Sell 309 K USD
|
Castellano Thomas P
SVP, Chief Financial Officer |
- 2307
|
134 USD |
|
3 years ago
Oct 14, 2021
|
Sell 215 K USD
|
Arnold Jonathan
Pres. Oral & Specialty Deliv. |
- 1661
|
129.41 USD |
|
3 years ago
Oct 04, 2021
|
Sell 288 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 2191
|
131.25 USD |
|
3 years ago
Oct 04, 2021
|
Sell 2.64 M USD
|
Fasman Steven L
SVP & General Counsel |
- 20513
|
128.56 USD |
|
3 years ago
Oct 04, 2021
|
Sell 1.06 M USD
|
Fasman Steven L
SVP & General Counsel |
- 8209
|
129.17 USD |
|
3 years ago
Oct 04, 2021
|
Sell 547 K USD
|
Fasman Steven L
SVP & General Counsel |
- 4192
|
130.39 USD |
|
3 years ago
Oct 04, 2021
|
Sell 236 K USD
|
Fasman Steven L
SVP & General Counsel |
- 1800
|
131.04 USD |
|
3 years ago
Oct 01, 2021
|
Sell 651 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 4906
|
132.68 USD |
|
3 years ago
Oct 01, 2021
|
Sell 25.6 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 200
|
128 USD |
|
3 years ago
Oct 01, 2021
|
Sell 12.9 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 100
|
129.05 USD |
|
3 years ago
Oct 01, 2021
|
Sell 54.6 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 416
|
131.14 USD |
|
3 years ago
Oct 01, 2021
|
Sell 177 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 1339
|
132.56 USD |
|
3 years ago
Oct 01, 2021
|
Sell 586 K USD
|
Chiminski John R
Chair & CEO |
- 4601
|
127.34 USD |
|
3 years ago
Oct 01, 2021
|
Sell 2.37 M USD
|
Chiminski John R
Chair & CEO |
- 18510
|
128.1 USD |
|
3 years ago
Oct 01, 2021
|
Sell 1.64 M USD
|
Chiminski John R
Chair & CEO |
- 12700
|
129.22 USD |
|
3 years ago
Oct 01, 2021
|
Sell 2.77 M USD
|
Chiminski John R
Chair & CEO |
- 21245
|
130.39 USD |
|
3 years ago
Oct 01, 2021
|
Sell 3.5 M USD
|
Chiminski John R
Chair & CEO |
- 26662
|
131.21 USD |
|
3 years ago
Oct 01, 2021
|
Sell 8.46 M USD
|
Chiminski John R
Chair & CEO |
- 64031
|
132.18 USD |
|
3 years ago
Oct 01, 2021
|
Sell 649 K USD
|
Chiminski John R
Chair & CEO |
- 4888
|
132.86 USD |
|
3 years ago
Aug 27, 2021
|
Sell 20.6 K USD
|
Castellano Thomas P
SVP, Chief Financial Officer |
- 158
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 254 K USD
|
Castellano Thomas P
SVP, Chief Financial Officer |
- 1935
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 8.21 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 63
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 100 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 762
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 14.5 K USD
|
Hopson Ricky
VP, Chief Accounting Officer |
- 111
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 178 K USD
|
Hopson Ricky
VP, Chief Accounting Officer |
- 1360
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 6.91 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 53
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 83.8 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 639
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 36.9 K USD
|
Maselli Alessandro
President & COO |
- 283
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 454 K USD
|
Maselli Alessandro
President & COO |
- 3460
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 22.5 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 173
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 278 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 2122
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 245 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 1878
|
130.34 USD |
|
3 years ago
Aug 27, 2021
|
Sell 16.7 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 128
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 206 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 1570
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 22.3 K USD
|
Gennadios Aristippos
President Softgel & Oral Tech |
- 171
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 274 K USD
|
Gennadios Aristippos
President Softgel & Oral Tech |
- 2091
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 60.1 K USD
|
Fasman Steven L
SVP & General Counsel |
- 461
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 741 K USD
|
Fasman Steven L
SVP & General Counsel |
- 5650
|
131.2 USD |
|
3 years ago
Aug 27, 2021
|
Sell 469 K USD
|
Chiminski John R
Chair & CEO |
- 3600
|
130.41 USD |
|
3 years ago
Aug 27, 2021
|
Sell 5.36 M USD
|
Chiminski John R
Chair & CEO |
- 40888
|
131.12 USD |
|
3 years ago
Aug 27, 2021
|
Sell 4.56 K USD
|
Arnold Jonathan
Pres. Oral & Specialty Deliv. |
- 35
|
130.29 USD |
|
3 years ago
Aug 27, 2021
|
Sell 54.7 K USD
|
Arnold Jonathan
Pres. Oral & Specialty Deliv. |
- 417
|
131.2 USD |
|
4 years ago
Dec 19, 2019
|
Sell 99.7 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 1846
|
54 USD |
|
4 years ago
Dec 20, 2019
|
Sell 135 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 2406
|
56 USD |
|
4 years ago
Jan 13, 2020
|
Sell 97.4 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 1680
|
58 USD |
|
3 years ago
Jul 26, 2021
|
Sell 62.7 K USD
|
Castellano Thomas P
SVP, Chief Financial Officer |
- 555
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 61.8 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 547
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 40.7 K USD
|
Hopson Ricky
VP, Chief Accounting Officer |
- 360
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 51.8 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 458
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 112 K USD
|
Maselli Alessandro
President & COO |
- 993
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 68.8 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 609
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 53.1 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 470
|
113.02 USD |
|
3 years ago
Jul 26, 2021
|
Sell 51 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 451
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 52.6 K USD
|
Gennadios Aristippos
President Softgel & Oral Tech |
- 465
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 175 K USD
|
Fasman Steven L
SVP & General Counsel |
- 1549
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 1.26 M USD
|
Chiminski John R
Chair & CEO |
- 11137
|
113.05 USD |
|
3 years ago
Jul 26, 2021
|
Sell 13.6 K USD
|
Arnold Jonathan
Pres. Oral & Specialty Deliv. |
- 120
|
113.05 USD |
|
3 years ago
Jul 15, 2021
|
Sell 363 K USD
|
Fasman Steven L
SVP & General Counsel |
- 3313
|
109.64 USD |
|
3 years ago
Jul 15, 2021
|
Sell 131 K USD
|
Fasman Steven L
SVP & General Counsel |
- 1187
|
110.46 USD |
|
3 years ago
Jun 23, 2021
|
Sell 310 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 2800
|
110.58 USD |
|
3 years ago
Mar 22, 2021
|
Sell 148 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 1400
|
105.77 USD |
|
3 years ago
Mar 18, 2021
|
Sell 1.35 M USD
|
Fasman Steven L
SVP & General Counsel |
- 12915
|
104.24 USD |
|
3 years ago
Mar 18, 2021
|
Sell 917 K USD
|
Fasman Steven L
SVP & General Counsel |
- 8732
|
104.96 USD |
|
3 years ago
Mar 19, 2021
|
Sell 7.46 M USD
|
Chiminski John R
Chair & CEO |
- 70583
|
105.64 USD |
|
3 years ago
Mar 19, 2021
|
Sell 11.9 M USD
|
Chiminski John R
Chair & CEO |
- 111641
|
106.24 USD |
|
3 years ago
Mar 18, 2021
|
Sell 4.44 M USD
|
Chiminski John R
Chair & CEO |
- 42220
|
105.16 USD |
|
3 years ago
Mar 19, 2021
|
Sell 85.7 K USD
|
Chiminski John R
Chair & CEO |
- 800
|
107.07 USD |
|
3 years ago
Feb 16, 2021
|
Sell 221 K USD
|
Joseph Wetteny
SVP & Chief Financial Officer |
- 1799
|
122.82 USD |
|
3 years ago
Feb 16, 2021
|
Sell 148 K USD
|
Joseph Wetteny
SVP & Chief Financial Officer |
- 1200
|
123.73 USD |
|
3 years ago
Feb 16, 2021
|
Sell 126 K USD
|
Joseph Wetteny
SVP & Chief Financial Officer |
- 1001
|
126.13 USD |
|
3 years ago
Feb 16, 2021
|
Sell 127 K USD
|
Joseph Wetteny
SVP & Chief Financial Officer |
- 1000
|
127 USD |
|
3 years ago
Feb 08, 2021
|
Sell 524 K USD
|
Joseph Wetteny
SVP & Chief Financial Officer |
- 4604
|
113.73 USD |
|
3 years ago
Jan 21, 2021
|
Sell 82.2 K USD
|
Whitlow Ricci S
President, CSS |
- 692
|
118.85 USD |
|
3 years ago
Jan 11, 2021
|
Sell 155 K USD
|
Flynn Karen
Pres. Biologics & CCO |
- 1378
|
112.14 USD |
|
3 years ago
Jan 11, 2021
|
Sell 124 K USD
|
Flynn Karen
Pres. Biologics & CCO |
- 1100
|
112.5 USD |
|
3 years ago
Jan 06, 2021
|
Sell 6.39 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 61
|
104.78 USD |
|
3 years ago
Jan 04, 2021
|
Sell 8.67 K USD
|
Whitlow Ricci S
President, CSS |
- 83
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 7.62 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 73
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 8.14 K USD
|
Pravda Ricardo
SVP & Chief HR Officer |
- 78
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 15.5 K USD
|
Maselli Alessandro
President & COO |
- 148
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 18 K USD
|
Joseph Wetteny
SVP & Chief Financial Officer |
- 172
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 12.5 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 120
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 13.2 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 126
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 11.5 K USD
|
Gennadios Aristippos
President Softgel & Oral Tech |
- 110
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 10.3 K USD
|
Flynn Karen
Pres. Biologics & CCO |
- 99
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 19.7 K USD
|
Fasman Steven L
SVP & General Counsel |
- 189
|
104.42 USD |
|
3 years ago
Jan 04, 2021
|
Sell 1.67 K USD
|
Arnold Jonathan
Pres. Oral & Specialty Deliv. |
- 16
|
104.42 USD |
|
3 years ago
Dec 21, 2020
|
Sell 405 K USD
|
Gennadios Aristippos
President Softgel & Oral Tech |
- 3936
|
102.95 USD |
|
3 years ago
Dec 21, 2020
|
Sell 1 M USD
|
Gennadios Aristippos
President Softgel & Oral Tech |
- 9726
|
102.8 USD |
|
3 years ago
Nov 23, 2020
|
Sell 535 M USD
|
Zippelius Peter
Director |
- 5392280
|
99.26 USD |
|
4 years ago
Nov 11, 2020
|
Sell 245 K USD
|
Fasman Steven L
SVP & General Counsel |
- 2425
|
100.99 USD |
|
4 years ago
Oct 14, 2020
|
Sell 109 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 1185
|
92.23 USD |
|
4 years ago
Oct 14, 2020
|
Sell 65 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 700
|
92.88 USD |
|
4 years ago
Oct 14, 2020
|
Sell 84.8 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 900
|
94.18 USD |
|
4 years ago
Oct 14, 2020
|
Sell 19 K USD
|
Schmidt Kay A
SVP, Technical Operations |
- 200
|
94.87 USD |
|
4 years ago
Oct 14, 2020
|
Sell 230 K USD
|
Fasman Steven L
SVP & General Counsel |
- 2489
|
92.31 USD |
|
4 years ago
Oct 14, 2020
|
Sell 9.29 K USD
|
Fasman Steven L
SVP & General Counsel |
- 100
|
92.88 USD |
|
4 years ago
Oct 14, 2020
|
Sell 132 K USD
|
Fasman Steven L
SVP & General Counsel |
- 1400
|
94.29 USD |
|
4 years ago
Oct 14, 2020
|
Sell 9.49 K USD
|
Fasman Steven L
SVP & General Counsel |
- 100
|
94.89 USD |
|
4 years ago
Oct 14, 2020
|
Sell 32.8 K USD
|
Fasman Steven L
SVP & General Counsel |
- 353
|
92.95 USD |
|
4 years ago
Oct 14, 2020
|
Sell 52.4 K USD
|
Fasman Steven L
SVP & General Counsel |
- 568
|
92.28 USD |
|
4 years ago
Oct 14, 2020
|
Sell 47.2 K USD
|
Fasman Steven L
SVP & General Counsel |
- 500
|
94.33 USD |
|
4 years ago
Oct 12, 2020
|
Sell 160 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 1680
|
94.99 USD |
|
4 years ago
Oct 07, 2020
|
Sell 1.46 M USD
|
Arnold Jonathan
Pres. Oral & Specialty Deliv. |
- 15928
|
91.5 USD |
|
4 years ago
Oct 02, 2020
|
Sell 229 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 2665
|
85.8 USD |
|
4 years ago
Oct 02, 2020
|
Sell 140 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 1645
|
84.94 USD |
|
4 years ago
Oct 02, 2020
|
Sell 4.22 K USD
|
Gunther Scott
SVP, Quality & Reg. Affairs |
- 49
|
86.22 USD |
|
4 years ago
Oct 02, 2020
|
Sell 784 K USD
|
Chiminski John R
Chair & CEO |
- 9191
|
85.27 USD |
|
4 years ago
Oct 02, 2020
|
Sell 14.9 M USD
|
Chiminski John R
Chair & CEO |
- 173040
|
86.05 USD |
|
4 years ago
Sep 02, 2020
|
Sell 201 K USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 2244
|
89.5 USD |
|
4 years ago
Sep 02, 2020
|
Sell 540 USD
|
Grippo Michael J
SVP, Strategy & Corp. Dev. |
- 6
|
90 USD |
7. News
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.
reuters.com
- 3 days ago
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
zacks.com
- 3 days ago
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.
zacks.com
- 1 week ago
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago.
zacks.com
- 1 week ago
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
reuters.com
- 1 week ago
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.
reuters.com
- 1 week ago
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
zacks.com
- 3 weeks ago
Roche comes out against clearing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
reuters.com
- 3 weeks ago
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.
reuters.com
- 3 weeks ago
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent , saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
reuters.com
- 1 month ago
Catalent Stock Flat Following the Sell Agreement With Ardena
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.
zacks.com
- 1 month ago
Catalent to sell New Jersey facility
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.
reuters.com
- 1 month ago
8. Profile Summary
Catalent, Inc. CTLT
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 10.7 B
Dividend Yield
0.00%
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Contact
14 Schoolhouse Road, Somerset, NJ, 08873
https://www.catalent.com
IPO Date
July 31, 2014
Employees
17000
Officers
Mr. Charles Lickfold
Senior Vice President & Chief Information Officer
Mr. John J. Greisch M.B.A.
Executive Chairman of the Board
Mr. Matti M. Masanovich
Senior Vice President & Chief Financial Officer
Ms. Lisa Evoli
Senior Vice President & Chief Human Resources Officer
Mr. Michael J. Hatzfeld Jr.
Vice President & Chief Accounting Officer
Mr. Paul Surdez
Vice President of Investor Relations
Mr. Ricky Hopson
President, Division Head for BioProduct Delivery & Chief of Staff
Mr. David McErlane
Group President of Biologics Segment
Mr. Joseph A. Ferraro J.D.
Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary
Mr. Alessandro Maselli
President, Chief Executive Officer & Director